enVVeno Medical reports Q1 EPS (22c) vs. (31c) last year

Robert Berman, enVVeno Medical’s (NVNO) Chief Executive Officer, commented “In the first quarter, we continued to present our compelling 1-year data from the U.S. pivotal trial at leading global, scientific conferences to socialize and engage directly with leading vascular surgeons as we lay the foundation for the potential phased market entry of the VenoValve, pending FDA approval. We have also maintained a strong financial position – an important advantage in the current market conditions. We remain confident that 2025 will be a pivotal year as we prepare for our transition from a development-stage company to a commercial enterprise.”